Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 369

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1C
Chunk 369
---
)
  
    Balance as of December 31, 2024 
     22,280,451  
    $22  
    $195,754  
    $(575) 
    $(163,104) 
    $32,097 

See accompanying notes to these consolidated financial
statements.

F-5

INMUNE BIO INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023

(In thousands)

    2024  
    2023 
  
    CASH FLOWS FROM OPERATING ACTIVITIES: 

    Net loss 
    $(42,082) 
    $(30,008)
  
    Adjustments to reconcile net loss to net cash used in operating activities: 

    Stock-based compensation 
     7,605  
     7,368 
  
    Accretion of debt discount 
     79  
     224 
  
    Changes in operating assets and liabilities: 

    Research and development tax credit receivable 
     724  
     6,194 
  
    Other tax receivable 
     309  
     (175)
  
    Prepaid expenses and other current assets 
     1,179  
     2,517 
  
    Prepaid expenses – related party 
     142  
     (108)
  
    Other assets 
     52  
     (32)
  
    Accounts payable and accrued liabilities 
     (1,362) 
     2,695 
  
    Accounts payable and accrued liabilities – related parties 
     (10) 
     26 
  
    Deferred liabilities 
     28  
     (127)
  
    Accrued liability – long-term 
     -  
     (550)
  
    Operating lease liability 
     (25) 
     (4)
  
    Net cash used in operating activities 
     (33,361) 
     (11,980)

    CASH FLOWS FROM FINANCING ACTIVITIES: 

    Net proceeds from sale of common stock and warrants 
     27,789  
     775 
  
    Repayment of debt 
     (10,000) 
     (5,000)
  
    Net proceeds from the exercise of stock options 
     422  
     -